

2<sup>nd</sup> Global Congress on  
**CANCER SCIENCE AND  
THERAPY**  
July 22-23, 2019 | Brussels, Belgium

CANCER CONGRESS 2019



**SCIENTIFIC TRACKS & ABSTRACTS  
DAY 1**

# DAY 1 SESSIONS

## JULY 22, 2019

Cancer Science to Clinical Trials | Immunotherapy in Cancer Science  
| Signalling Pathways in Cancer

### SESSION CHAIR

Walid Odeh  
German Board in Oral Implantology, Germany

### SESSION INTRODUCTION

**Title:** The treatment of pancreatic cancer with NSC-631570 (Ukraine)  
Wassil Nowicky, Ukrainian Anti-Cancer Institute, Austria

# CANCER SCIENCE AND THERAPY

July 22-23, 2019 | Brussels, Belgium

Wassil Nowicky, J Cancer Immunol Ther 2019, Volume 2

## THE TREATMENT OF PANCREATIC CANCER WITH NSC-631570 (UKRAIN)

### Wassil Nowicky

Ukrainian Anti-Cancer Institute, Austria

Despite the fact that increasing amount of resources is put into the treatment of pancreatic cancer, one of the most aggressive and lethal forms of cancerous diseases are the therapeutical outcome remains poor. Chemotherapeutic agents such as Gemcitabine were found to have a positive influence on the quality of life in pancreatic cancer patients; however, median survival times in patients treated with gemcitabine were only marginally prolonged. Protocols using combinations of gemcitabine with 5-fluorouracil with or without folinic acid or combinations of gemcitabine and cisplatinium have prolonged median survival, however these results remain unsatisfactory. As such, finding a therapeutic agent that can further extend the median survival as well as improve the quality of life of patients with pancreatic cancer remains a top priority. In recent years research with the anti-cancer preparation NSC-631570 (Ukraine) has shown promising results in the treatment of unresectable pancreatic cancer with actuarial survival rates of 86.7% after one year, 76.6% after two years, 46.7% after three years and 23.3% after five years and a median survival time according to Kaplan-Meier regression analysis of 33.8 months. These promising clinical results justified further research on the exact mechanism of action as well as further possible beneficial effects of NSC-631570.

## BIOGRAPHY

Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) in 1955 with graduation to "Diplomingenieur" in 1960 which title was nostrificated in Austria in 1975. He became the very first scientist in the development of the anticancer protonic therapy and is the Inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids "NSC-631570". He used the factor that cancer cells are more negative charged than normal cells and invented the celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. He has been invited as an Honorable Speaker in many scientific international congresses and conferences in USA, Australia, Japan, UAE and Europe. He has over 300 scientific articles dedicated to cancer research. He is a Member of the New York Academy of Sciences, European Union for Applied Immunology and of the American Association for Scientific Progress, Honorary Doctor of the Janka Kupala State University in Grodno, Doctor "Honoris Causa" of the Open International University on Complex Medicine in Colombo, Honorary Member of the Austrian Society of a name of Albert Schweizer. He has received the award of merits from National Guild of Pharmacists of America, the Award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.

[dr.nowicky@yahoo.de](mailto:dr.nowicky@yahoo.de)



Note: